Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

January 6, 2003

Briefing Information

COZAAR™ (losartan potassium)

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Losartan Potassium - LIFE Study, Merck Research Laboratories (PDF)

Cozaar™ Clinical Review, FDA. (HTM) (PDF) (Word)

Cozaar™ Clinical Review Errata (HTM) (PDF) (Word)

Cozaar™ Statistical Review, FDA (HTM) (PDF) (Word)